Corcept Therapeutics (CORT) Treasury Shares (2013 - 2026)

Corcept Therapeutics has disclosed Treasury Shares across 9 years of filings, most recently posting $976.7 million for Q1 2026.

• Treasury Shares for Q1 2026 came in at $976.7 million, up 31.15% year-over-year; the trailing twelve-month figure through Mar 2026 was $976.7 million (up 31.15% YoY), and the FY2025 annual result was $966.6 million, up 38.84% from the prior year.
• Treasury Shares came in at $976.7 million for Q1 2026 at Corcept Therapeutics, up from $966.6 million in the prior quarter.
• In the past five years, Treasury Shares ranged from a high of $23.4 million in Q1 2023 to a low of $20000.0 in Q1 2024.
• The 5-year median for Treasury Shares is $910000.0 (2021), against an average of $2.6 million.
• Across the five-year window, Treasury Shares jumped 216.6% in 2022 and grew 5.97% in 2024, its largest moves.
• Corcept Therapeutics' Treasury Shares stood at $456.1 million in 2022, then surged by 39.23% to $635.1 million in 2023, then rose by 9.62% to $696.2 million in 2024, then jumped by 38.84% to $966.6 million in 2025, then rose by 1.05% to $976.7 million in 2026.
• The last three Treasury Shares figures came in at $976.7 million (Q1 2026), $966.6 million (Q4 2025), and $923.3 million (Q3 2025), per Business Quant data.